Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients

被引：11
|
作者：
Trombetta, Claudia Maria [1 ]
Marchi, Serena [1 ]
Viviani, Simonetta [1 ]
Manenti, Alessandro [2 ]
Benincasa, Linda [3 ]
Ruello, Antonella [4 ]
Bombardieri, Emilio [4 ]
Vicenti, Ilaria [5 ]
Zazzi, Maurizio [5 ]
Montomoli, Emanuele [1 ,2 ,3 ]
机构：
[1] Univ Siena, Dept Mol & Dev Med, I-53100 Siena, Italy
[2] VisMederi Srl, Str Petriccio & Belriguardo 35, I-53100 Siena, Italy
[3] VisMederi Res Srl, Str Petriccio & Belriguardo 35, I-53100 Siena, Italy
[4] Humanitas Gavazzeni, Via Mauro Gavazzeni 21, I-24125 Bergamo, Italy
[5] Univ Siena, Dept Med Biotechnol, I-53100 Siena, Italy
来源：
VIRUSES-BASEL | 2021年 / 13卷 / 07期
基金：
欧盟地平线“2020”;
关键词：
neutralizing activity; SARS-CoV-2; variants of concern;
D O I：
10.3390/v13071347
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The recent spreading of new SARS-CoV-2 variants, carrying several mutations in the spike protein, could impact immune protection elicited by natural infection or conferred by vaccination. In this study, we evaluated the neutralizing activity against the viral variants that emerged in the United Kingdom (B.1.1.7), Brazil (P.1), and South Africa (B.1.351) in human serum samples from hospitalized patients infected by SARS-CoV-2 during the first pandemic wave in Italy in 2020. Of the patients studied, 59.5% showed a decrease (>= 2 fold) in neutralizing antibody titer against B.1.1.7, 83.3% against P.1, and 90.5% against B.1.351 with respect to the original strain. The reduction in antibody titers against all analyzed variants, and in particular P.1 and B.1.351, suggests that previous symptomatic infection might be not fully protective against exposure to SARS-CoV-2 variants carrying a set of relevant spike mutations.
引用
收藏
页数：9
相关论文
共 50 条
  • [31] Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants
    Chandrashekar, Abishek
    Liu, Jinyan
    Yu, Jingyou
    McMahan, Katherine
    Tostanoski, Lisa H.
    Jacob-Dolan, Catherine
    Mercado, Noe B.
    Anioke, Tochi
    Chang, Aiquan
    Gardner, Sarah
    Giffin, Victoria M.
    Hope, David L.
    Nampanya, Felix
    Patel, Shivani
    Sanborn, Owen
    Sellers, Daniel
    Wan, Huahua
    Martinot, Amanda J.
    Baczenas, John J.
    O'Connor, Shelby L.
    Pessaint, Laurent
    Valentin, Daniel
    Espina, Benjamin
    Wattay, Lauren
    Ferrari, Maria G.
    Brown, Renita
    Cook, Anthony
    Bueno-Wilkerson, Deandre
    Teow, Elyse
    Andersen, Hanne
    Lewis, Mark G.
    Barouch, Dan H.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2021, 13 (618)
  • [32] Emergence and Spread of SARS-CoV-2 Lineages B.1.1.7 and P.1 in Italy
    Di Giallonardo, Francesca
    Puglia, Ilaria
    Curini, Valentina
    Camma, Cesare
    Mangone, Iolanda
    Calistri, Paolo
    Cobbin, Joanna C. A.
    Holmes, Edward C.
    Lorusso, Alessio
    [J]. VIRUSES-BASEL, 2021, 13 (05):
  • [33] Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines
    Yang, Yong
    Zang, Jinkai
    Xu, Shiqi
    Zhang, Xueyang
    Yuan, Sule
    Wang, Haikun
    Lavillette, Dimitri
    Zhang, Chao
    Huang, Zhong
    [J]. VIRUSES-BASEL, 2021, 13 (08):
  • [34] Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France
    Charmet, Tiffany
    Schaeffer, Laura
    Grant, Rebecca
    Galmiche, Simon
    Cheny, Olivia
    Von Platen, Cassandre
    Maurizot, Alexandra
    Rogoff, Alexandra
    Omar, Faiza
    David, Christophe
    Septfons, Alexandra
    Cauchemez, Simon
    Gaymard, Alexandre
    Lina, Bruno
    Lefrancois, Louise H.
    Enouf, Vincent
    van der Werf, Sylvie
    Mailles, Alexandra
    Levy-Bruhl, Daniel
    Carrat, Fabrice
    Fontanet, Arnaud
    [J]. LANCET REGIONAL HEALTH-EUROPE, 2021, 8
  • [35] ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7
    Fischer, Robert J.
    van Doremalen, Neeltje
    Adney, Danielle R.
    Yinda, Claude Kwe
    Port, Julia R.
    Holbrook, Myndi G.
    Schulz, Jonathan E.
    Williamson, Brandi N.
    Thomas, Tina
    Barbian, Kent
    Anzick, Sarah L.
    Ricklefs, Stacy
    Smith, Brian J.
    Long, Dan
    Martens, Craig
    Saturday, Greg
    de Wit, Emmie
    Gilbert, Sarah C.
    Lambe, Teresa
    Munster, Vincent J.
    [J]. NATURE COMMUNICATIONS, 2021, 12 (01)
  • [36] Coding-Complete Genome Sequences of 11 SARS-CoV-2 B.1.1.7 and B.1.351 Variants from Metro Manila, Philippines
    Mark Velasco, John
    Chinnawirotpisan, Piyawan
    Valderama, Maria Theresa
    Joonlasak, Khajohn
    Manasatienkij, Wudtichai
    Huang, Angkana
    Diones, Paula Corazon
    Claire Navarro, Fatima
    Vila, Vicente, II
    Tabinas Jr, Henry
    Chua Jr, Domingo
    Fernandez, Stefan
    Jones, Anthony
    Klungthong, Chonticha
    [J]. MICROBIOLOGY RESOURCE ANNOUNCEMENTS, 2021, 10 (28):
  • [37] Severity of infection with the SARS-CoV-2 B.1.1.7 lineage among hospitalized COVID-19 patients in Belgium
    Van Goethem, Nina
    Vandromme, Mathil
    Van Oyen, Herman
    Haarhuis, Freek
    Brondeel, Ruben
    Catteau, Lucy
    Andre, Emmanuel
    Cuypers, Lize
    Blot, Koen
    Serrien, Ben
    [J]. PLOS ONE, 2022, 17 (06):
  • [38] Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants
    Bayarri-Olmos, Rafael
    Jarlhelt, Ida
    Johnsen, Laust Bruun
    Hansen, Cecilie Bo
    Helgstrand, Charlotte
    Bjelke, Jais Rose
    Matthiesen, Finn
    Nielsen, Susanne Dam
    Iversen, Kasper Karmark
    Ostrowski, Sisse Rye
    Bundgaard, Henning
    Frikke-Schmidt, Ruth
    Garred, Peter
    Skjoedt, Mikkel-Ole
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [39] The Natural Stilbenoid (-)-Hopeaphenol Inhibits Cellular Entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7, and B.1.351 Variants
    Tietjen, Ian
    Cassel, Joel
    Register, Emery T.
    Zhou, Xiang Yang
    Messick, Troy E.
    Keeney, Frederick
    Lu, Lily D.
    Beattie, Karren D.
    Rali, Topul
    Tebas, Pablo
    Ertl, Hildegund C. J.
    Salvino, Joseph M.
    Davis, Rohan A.
    Montaner, Luis J.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (12)
  • [40] TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351)
    Lee, Jihye
    Lee, JinAh
    Kim, Hyeon Ju
    Ko, Meehyun
    Jee, Youngmee
    Kim, Seungtaek
    [J]. MICROBIOLOGY SPECTRUM, 2021, 9 (01): : 1 - 7
12345